DiaSorin S.p.A.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Carlo Rosa
- Full Time Employees
- 3,272
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Via Crescentino snc Saluggia VC Italy 13040
- IPO Date
- Jul 3, 2007
- Website
- diasorin.com
- Similar Companies
- Business
- DiaSorin S.p.A. (DIA.MI) develops, manufactures and markets reagent kits for immunodiagnostics and molecular diagnostics used by clinical laboratories worldwide to aid in patient diagnosis, health monitoring and disease progression assessment; its core offerings include automated platforms such as LIAISON for chemiluminescent immunoassays covering infectious diseases, bone and mineral metabolism, endocrinology, hypertension, oncology, autoimmunity, gastrointestinal infections and cardiac markers, as well as molecular diagnostic tests for infectious diseases and leukemias utilizing blood, cerebrospinal fluid and swab samples, complemented by licensed technologies in life sciences including xMAP multiplexing and flow cytometry following the 2021 acquisition of Luminex Corporation. The company operates through 35 subsidiaries and branches across five continents, with manufacturing sites and R&D centers in Europe, North America and Asia, targeting hospital labs, reference laboratories and research institutions. Founded in 1968 and headquartered in Saluggia, Italy, DiaSorin expanded its molecular diagnostics portfolio via the $1.8 billion Luminex acquisition in July 2021, integrating Nanosphere Inc. for advanced infectious disease detection via the Verigene System, and advanced its 2022-2025 strategic plan through new platform launches including LIAISON MDX Plus, LIAISON Plex and LIAISON NES for multiplex and near-patient testing, alongside partnerships such as with B·R·A·H·M·S (Thermo Fisher Scientific) for LIAISON B·R·A·H·M·S MR-proADM and QIAGEN for latent tuberculosis screening.
Company News
DiaSorin (OTCMKTS:DSRLF) Shares Down 1.7% – Should You Sell?
DiaSorin S.p.A. (DSRLF) Q2 2026 Earnings Call Transcript
DiaSorin S.p.A. (DSRLF) Q1 2026 Earnings Call Transcript
Head to Head Contrast: Perrigo (NYSE:PRGO) and DiaSorin (OTCMKTS:DSRLF)
DiaSorin S.p.A. (DSRLF) Q4 2025 Earnings Call Transcript
Head-To-Head Survey: Abbott Laboratories (NYSE:ABT) vs. DiaSorin (OTCMKTS:DSRLF)
Head-To-Head Review: IM Cannabis (NASDAQ:IMCC) versus DiaSorin (OTCMKTS:DSRLF)
Invesco International Small-Mid Company Fund Q3 2025 Portfolio Positioning
DiaSorin: Anticipate A Double-Digit EBITDA Growth Rate
DiaSorin S.p.A. (DSRLF) Q4 2024 Earnings Call Transcript
Italy's DiaSorin ex-Covid revenue in line with guidance
DiaSorin S.p.A. (DSRLF) Q2 2024 Earnings Call Transcript
DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript
Diasorin 2023 revenue drops 14%, in line with guidance; shares fall
New Strong Sell Stocks for January 29th
DiaSorin S.p.A. (DSRLF) Q3 2023 Earnings Call Transcript
DiaSorin S.p.A. (DSRLF) Q2 2023 Earnings Call Transcript
DiaSorin S.p.A. (DSRLF) Q4 2022 Earnings Call Transcript
DiaSorin: Overvalued Italian Healthcare Company
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2022 Results - Earnings Call Transcript